-
Mashup Score: 41
Gastroenteropancreatic neuroendocrine neoplasms(GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO introduced the neuroendocrine tumour(NET) grade 3 (G3) subgroup, characterized by Ki-67>20% and a well-differentiated morphology and poorly differentiated neuroendocrine carcinomas(NEC) (Ki-67>20%). Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain. Therefore we initiated a real-world retrospective observational cohort study, using data from 225 NEC and 58 NET G3 patients treated in Belgium. Analysis of patient and tumour characteristics and the effect of survival was conducted. Most frequent primary locations were pancreatic (32.9%) and colorectal (21.5%), and 71.8% was diagnosed with stage IV disease. Median overall survival(mOS) was higher in NET G3 (41.3 months(m)) compared to NEC (13.2m). Of those who underwent functional imaging, fluorodeoxyglucose-po
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
The predictive value of the extent of peri-operative lymph node (LN) sampling in relation to disease relapse in patients with pulmonary carcinoid (PC) is unknown. Furthermore, post-surgery follow-up recommendations rely on institutional retrospective studies with short follow-ups. We aimed to address these shortcomings by examining the relation between LN sampling and relapse in a population-based cohort with long-term follow-up. By combining the Dutch nationwide pathology and cancer registries, all patients with surgically resected PC (2003–2012) were included in this analysis (last update 2020). The extent of surgical LN dissection was scored for the number of LN samples, location (hilar/mediastinal), and completeness of resection according to European Society of Thoracic Surgeons (ESTS) guidelines. Relapse-free interval (RFI) was evaluated using Kaplan Meier and multivariate regression analysis. 662 patients were included. The median follow-up was 87.5 months. Relapse occurred in 10
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
There are 3 lessons (well, there are more but I am too lazy tonight): 1) Relapses occur, according to one recent study in 10% of pts with resected disease and more often in atypical carcinoid, LN+ and incompletely resected disease. @DerksJules https://t.co/tfqgM4iM8B
-
-
Mashup Score: 37Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature - 6 month(s) ago
The classification and management of neuroendocrine neoplasms (NENs) arising in the tubular gastrointestinal (GI) tract and pancreas have significantly evolved over the last decades. In the latest WHO classification published in 2022, NEN are separated regardless of their primary origin into two main groups: well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The substantial changes in grading system changed the definition of grade 3 to include high grade well differentiated NETs (G3-NETs), and poorly differentiated NECs (-NECs). Although, these two subgroups are considered high grades with Ki-67 >20%, they have different genomic profiles, prognosis and clinical behavior which critically influence their treatment strategies. The available clinical trial data to guide therapy of these high-grade subgroups are extremely limited which impact their management. In this review, we will summarize the current advances in the multidiscipl
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
Need some guidance on the management of high-grade gastroenteropancreatic neuroendocrine neoplasms (GEPNENs)...? We have you covered thanks to Amr Mohamed at University Hospitals in Cleveland Seidman Cancer Center and team incl. @sonbol_bassam 😀 https://t.co/Zp0uGHFKvj
-
-
Mashup Score: 27Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study - 8 month(s) ago
Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical and atypical carcinoids [TCs and ACs]). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-blind study of lanreotide autogel/depot (LAN; 120 mg every 28 days) plus best supportive care (BSC) versus placebo plus BSC, with an optional open label treatment phase (LAN plus BSC). Patients had metastatic/unresectable, somatostatin receptor (SSTR)-positive TCs or ACs. Recruitment was stopped early owing to slow accrual; eligible patients from the double-blind phase transitioned to open-label LAN. The adapted primary endpoint was progression free survival (PFS) during either phase for patients receiving LAN. Seventy-seven patients were randomized (LAN, n=51 [TCs, n=29; ACs, n=22]; placebo, n=26 [TCs, n=16; ACs, n=10). Median (95% confidence interval [CI]) PFS during double-blind and OL phases in patients receiving LAN was 16.6 (11.3; 21.9) month
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
The SPINET trial is finally coming out in print. Lanreotide vs. placebo for lung NETs. I'm still bummed how poorly this important trial enrolled and that's a discussion for a different day... Bottom line: Lanreotide may work but the trial stopped early. https://t.co/ivlzHFVikw
-
-
Mashup Score: 20
The predictive value of extent of per-operative lymph node (LN) sampling in relation to disease relapse in patients with pulmonary carcinoid (PC) is unknown. Furthermore, post-surgery follow-up recommendations rely on institutional retrospective studies with rather short follow-up. We aimed to address these short-comings by examining the relation between LN sampling and relapse in a population-based cohort with long-term follow-up. By combining the Dutch nation-wide pathology and cancer registries, all patients with surgically resected PC (2003-2012) were included in this analysis (last update 2020). Extent of surgical LN dissection was scored for number of LN sampled, location (hilar/mediastinal), and completeness of resection according to European Society of Thoracic Surgeons (ESTS) guidelines. Relapse free interval (RFI) was evaluated using Kaplan Meier and multivariate regression analysis. 662 patients were included. Median follow-up was 87.5 months. Relapse occurred in 10% of pati
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
Recurrences in lung NETs are very real but patients do not always have the needed follow-up. In this study, 10% of resected lung NETs (TC 54%, AC 22%) recurred, often in the liver and not surprisingly, AC, LN+ and R1/R2 predicted recurrence. @DerksJules https://t.co/RMypmmXypi
-
-
Mashup Score: 28Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer - 10 month(s) ago
Androgen receptor signaling is crucial for the development of treatment resistance in prostate cancer. Among steroidogenic enzymes, 3β-hydroxysteroid dehydrogenases (3βHSDs) play critical roles in extragonadal androgen synthesis, especially 3βHSD1. Increased expression of 3βHSDs is observed in castration-resistant prostate cancer tumors compared with primary prostate tumors, indicating their involvement in castration resistance. Recent studies link 3βHSD1 to resistance to androgen receptor signaling inhibitors. The regulation of 3βHSD1 expression involves various factors, including transcription factors, microenvironmental influences, and post-transcriptional modifications. Additionally, the clinical significance of HSD3B1 genotypes, particularly the rs1047303 variant has been extensively studied. The impact of HSD3B1 genotypes on treatment outcomes varies according to the therapy administered, suggesting the potential of HSD3B1 genotyping for personalized medicine. Targeting 3βHSDs ma
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
Interesting review on 3βHSD1 in prostate cancer just out from the group in Kyushu @Endocancer @Soc_Endo. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer https://t.co/BkEsvUXLYu
-
-
Mashup Score: 33
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%) and ATRX (12%). 23/25 (92%) patients underwent tumor tissue NGS. Tissue-plasma concordance for select genes was DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially ac
Source: erc.bioscientifica.comCategories: General Medicine News, Hem/OncsTweet-
cfDNA for panc NETs...? 25 mostly well diff pNETs. Genomic alterations in 66% of samples with high concordance with tissue testing for many (e.g.DAXX, ATRX, ARID1A) alterations and potentially actionable alterations detected in 32%. @DianeReidyLagun https://t.co/4adhOKrMvV
-
-
Mashup Score: 6MEN1-related PanNETs: identifying unmet clinical needs and future directives in: Endocrine-Related Cancer - Ahead of print - 5 year(s) ago
…
Source: erc.bioscientifica.comCategories: Hem/Oncs, Latest HeadlinesTweet-
It's been a remarkable decade as a patient-advocate. I went from finding tumors on my pancreas 10 years ago to being invited to contribute my perspective to a position paper on how to manage MEN1 from experts @MDAndersonNews @NIH @UMCU_Intl & elsewhere! https://t.co/Sga8FeXWGM
-
-
Mashup Score: 2
This site uses cookies, tags and tracking settings to store information that help give you the very best browsing experience. If you don’t change your settings, we’ll assume you’re happy with this. More information Dismiss this warning …
Source: erc.bioscientifica.comCategories: UrologyTweet-
Are #androgens hazardous with #COVID-19? Does this explain worse outcomes in men? Several mechanisms possible including regulation of 1) TMPRSS2 expression 2) immune stim 3) adrenal steroid metabolism. Just my thoughts with @charlesryanmd https://t.co/f0f2mRdXCS
-
Functional imaging in NECs and much more... Check out this excellent paper. Lots of goodies in here such as >90% of NECs and G3 NETs FDG PET pos. Also, 66% of NECs pos on SSTR PET. What does that mean? The SSTR is not (yet) a good NEC target. @WLybaert https://t.co/O4tDVLpMTt